Introduction {#sec1}
============

Erythema dyschromicum perstans (EDP) is an acquired hyperpigmentation disorder characterized by asymptomatic, polycyclic, irregularly shaped light lilac-grey patches surrounded by erythematous borders in the early inflammatory stage and subsequently greyish-blue patches in the later ashy stage. Affected areas include the trunk, neck, face, and upper extremities. Mucous membranes are spared.[@bib1] EDP occurs in both children and adults, has a higher frequency noted in women, and is common among Latin American, Asian, and Indian populations.[@bib2], [@bib3], [@bib4] The cause remains largely unknown; however, proton pump inhibitors,[@bib5] radioactive contrast,[@bib6] hypothyroidism, vitiligo,[@bib7] and parasitic and hepatitis C infections,[@bib1] are among the associations with EDP.

Histopathologic findings of EDP include vacuolar interface dermatitis and pigment incontinence.[@bib4] EDP is histopathologically indistinguishable from lichen planus pigmentosus[@bib8]; however, distinct clinical characteristics separate the 2 disorders with lichen planus pigmentosus characterized by pruritic, brown-black macules and patches on the face, upper extremities, and flexures with occasional involvement of mucous membranes.[@bib1]

EDP is cosmetically disfiguring and poses as a therapeutic challenge. Multiple treatments have been proposed that show inconsistent efficacy. Among these are topical steroids, tretinoin, hydroquinone, clofazimine, dapsone, lasers, and narrow-band ultraviolet light B phototherapy.[@bib4] A single case is reported each for the use of isotretinoin[@bib9] and prednisone.[@bib10] In this case series of 4 adult patients with EDP, we report that a combined treatment regimen of prednisone and isotretinoin initiated in the early inflammatory stage leads to rapid resolution of the erythematous border, arrest of progression, and clearance of the hyperpigmentation.

Cases {#sec2}
=====

Case 1 {#sec2.1}
------

A 54-year-old Hispanic woman with a history of hypothyroidism presented with polycyclic light grey patches with a surrounding erythematous border on the shoulders, arms, forearms, and chest ([Fig 1](#fig1){ref-type="fig"}, *A*). A skin biopsy was consistent with EDP ([Fig 1](#fig1){ref-type="fig"}, *D*). The patient started topical triamcinolone 0.1% cream daily in conjunction with a 3-week prednisone taper as follows: 60 mg/d for 1 week followed by 40 mg/d for 1 week, followed by 20 mg/d for 1 week. Following the prednisone taper, marked improvement of the surrounding erythematous borders were noted ([Fig 1](#fig1){ref-type="fig"}, *B*). In addition to the prednisone, the patient was also started on isotretinoin, which was gradually tapered over 5 months as follows: 40 mg/d for 1 month, followed by 20 mg/d for 3 months, followed by 10 mg/d for 1 month. When therapy was completed, the patient showed substantial improvement with nearly complete resolution. At 10-month follow up, there was no evidence of disease recurrence ([Fig 1](#fig1){ref-type="fig"}, *C*). However, at the 16-month follow-up the patient had mild relapse on the bilateral legs; the prednisone taper and isotretinoin were restarted with improvement already evident after 4 weeks of retreatment.Fig 1EDP, case 1. **A,** At baseline, a large gray-to-blue irregularly shaped discrete patch with a surrounding erythematous border on the posterior shoulder. **B,** Marked improvement of the surrounding erythematous borders following prednisone taper. **C,** Complete resolution at 10-month follow-up. **D,** Cell-poor interface dermatitis with vacuolar degeneration of basilar keratinocytes and prominent pigment incontinence. (Hematoxylin-eosin stain; original magnification: ×200.)

Case 2 {#sec2.2}
------

A 47-year-old Hispanic woman with no medical history presented with multiple irregularly shaped light gray-to-lilac patches with surrounding erythematous borders on the arms, forearms, and neck ([Fig 2](#fig2){ref-type="fig"}, *A*). The patient was started on topical halobetasol 0.05% ointment daily in conjunction with a 3-week prednisone taper as follows: 60 mg/d for 1 week, followed by 40 mg/d for 1 week, followed by 20 mg/d for 1 week. After 3 weeks, the patient showed marked improvement with complete resolution of erythematous borders and improvement of the hyperpigmentation ([Fig 2](#fig2){ref-type="fig"}, *B*). Nine months later, the patient presented to clinic with relapsed disease. The 3-week prednisone taper was restarted, which again led to significant improvement, so she was transitioned to isotretinoin, 40 mg/d, which was tapered over the next 4 months as follows: 40 mg/d for 1 month, followed by 20 mg/d for 2 months, followed by 10 mg/d for the final month. Upon completion of treatment, the patient had sustained improvement without disease recurrence at 24 months.Fig 2EDP, case 2. **A,** Multiple irregularly shaped gray-to-blue patches with a surrounding erythematous border on the left volar forearm at baseline. **B,** Faint residual pigmentation with disappearance of the erythematous borders following the 3-week prednisone taper.

Case 3 {#sec2.3}
------

A 54-year-old Hispanic woman with a history of Sjogren syndrome and fibromyalgia presented with multiple ill-defined gray-to-blue patches on the volar aspects of her bilateral upper extremities. Skin biopsy was consistent with EDP. The patient was started on topical halobetasol 0.05% ointment daily in conjunction with a 3-week prednisone taper as follows: 60 mg/d for 1 week, followed by 40 mg/d for 1 week, followed by 20 mg/d for 1 week. Significant improvement was noted after the prednisone taper. The patient was then transitioned to a 3-month course of isotretinoin as follows: 20 mg/d for 2 months followed by 10 mg/d for the final month. At the completion of treatment, there was no evidence of erythema or pigmentation. Two months after discontinuation of isotretinoin, the patient reported relapse but declined further treatment.

Case 4 {#sec2.4}
------

A 54-year-old Hispanic woman with a history of diabetes and hypertension presented with multiple polycyclic hyperpigmented patches and surrounding erythematous borders coalescing on the medial aspect of the bilateral arms and forearms. Skin biopsy was consistent with EDP, and the patient was started on topical halobetasol 0.05% ointment daily in conjunction with a 3-week prednisone taper as follows: 60 mg/d for 1 week, followed by 40 mg/d for 1 week, followed by 20 mg/d for 1 week. At the completion of the prednisone taper, the affected areas were substantially improved with resolution of the surrounding erythematous borders. Thereafter, isotretinoin, 20 mg/d, was initiated. After only 1 month of isotretinoin, the patient discontinued treatment because of satisfaction with the clinical improvement, and reported no signs of relapse 2 months later.

Discussion {#sec3}
==========

Also known as *ashy dermatosis*, EDP is a chronic progressive hyperpigmentation disorder of unknown etiology, first described in 1957.[@bib4] EDP classically presents as asymptomatic, gray-to-blue patches with an erythematous border in a symmetrical distribution over the neck, trunk, and upper extremities.[@bib1] Histopathologic findings, although not specific, show variation depending on the stage of evolution. Acute or early inflammatory patches display basal vacuolar degeneration, papillary dermal edema, and perivascular lymphocytic inflammation. In contrast, chronic lesions show abundant melanophages and pigment incontinence, with diminished-to-absent inflammation, features that may be indistinguishable from postinflammatory hyperpigmentation of other causes.[@bib2]

To date, no randomized, placebo-controlled clinical trials have been conducted to determine standard therapeutic modalities and appropriate dosing regimens for the management of EDP. Some retrospective studies proposed numerous therapeutic agents, but results are inconsistent. Therapies reported from the years 2000 until now are summarized in [Supplemental Table I](#tbl1){ref-type="table"}. There is clearly an unmet need for consistently effective treatment. In this case series, we are the first, to our knowledge, to report a combination therapy of prednisone and isotretinoin in the early inflammatory stage of EDP.Supplemental Table ISummary of previous therapies used in erythema dyschromicum perstansYear, StudyStudy typeno, SexAge range (yr)EthnicityTherapies usedReported treatment outcomes2018,[@bib13]Retrospective study26, NA16-65AsianTopicals: steroid, hydroquinone, tacrolimus, tretinoin; oral steroidFive showed improvement following combined topical hydroquinone and steroid; remaining showed stable disease at 0.5- to 3-mo follow-up2018,[@bib14]Case report1 Male17NANarrow-band UVB, topical clobetasol and tacrolimusSustained resolution at 4-yr follow-up2017,[@bib15]Case report1 Female57WhiteClofazimineNo improvement2017,[@bib16]Case report1 Female35NAFractionated nonablative laser and tacrolimus ointmentImprovement \>75% and maintained at 5-mo follow-up2016,[@bib17]Case report1 Male48AsianIsotretinoinRecurrence upon discontinuation of treatment.2015,[@bib18]Retrospective study39 Female; 29 Male3-76AsianTopicals: steroid, tretinoin, hydroquinone; dapsone, clofazimine, minocyclineMost exhibited no improvement or worsened progression at \>1-yr follow-up2015,[@bib19]Case report1 Female; 1 Male19, 29NATopical tacrolimusResolution following therapy with no recurrence at 2- to 3-mo follow-up2015,[@bib20]Case report2 Female53, 59NANarrow-band UVBImprovement noted2015,[@bib21]Case report1 Female25HispanicTopical clobetasol, pimecrolimus, tacrolimus; dapsoneNo response to therapies; self-resolution noted at 5-yr follow-up2012,[@bib22]Preliminary study4 Female; 4 Male20-54NANonablative fractional laserNo improvement2012,[@bib23]Randomized, observer-blinded study6, NANANANonablative fractional laser therapyNo improvement2011,[@bib24]Case report1 Female11, 21AsianQ-switched ruby laserNo improvement1 Male2010,[@bib25]Case report1 Male39HispanicNarrow-band UVBImprovement following therapy2009,[@bib26]Case report1 Female34NAClofazimineResolution following therapy2004,[@bib27]Case report1 Male16NADapsoneResolution following therapy2001,[@bib28]Case report1 Male21HispanicPrednisoneImprovement following therapy2001,[@bib29]Case report1 Female48NAInterferon-α and ribavirinImprovement following therapy[^1]

As demonstrated in all cases presented, prednisone appears to both rapidly clear the erythematous border and improve the dyspigmentation, with significant improvement noted after only 3 weeks of treatment. The addition of isotretinoin appears to clear residual hyperpigmentation and maintain remission. Immune dysregulation in EDP is driven by interleukin-2, interferon-γ, natural killer cells, and cytotoxic CD8^+^ T cells,[@bib11] which may be modulated by prednisone and isotretinoin.[@bib9]^,^[@bib10]^,^[@bib12]

In this series no patient experienced significant adverse effects. Two of the 4 patients relapsed after stopping isotretinoin, which indicates that long-term treatment may be required to maintain remission. This finding mirrors the only previously reported case of EDP treated with isotretinoin in which the patient experienced relapse within 2 months of stopping isotretinoin and required long-term isotretinoin to maintain remission.[@bib9] The specific treatment regimens used and patient characteristics from this series are summarized in [Supplemental Table II](#tbl2){ref-type="table"}. In our experience, for the combined effect of prednisone and isotretinoin to be maximally successful, EDP should be treated at its earliest inflammatory stage, which is represented by light grey-to-lilac patches with a surrounding erythematous border. We feel it is imperative to recognize EDP early and initiate treatment immediately to achieve optimal response.Supplemental Table IIClinical demographics and treatment outcomesNo.Age (yr)SexEthnicityMedical historyTreatment regimenTreatment outcome154FemaleHispanicHypothyroidismTriamcinolone 0.1% cream\
3-wk prednisone taper (60 mg: 40:20)\
5-mo isotretinoin taper (40 mg: 20:20:20:10)Complete resolution but with mild relapse after 16 mo247FemaleHispanicNoneHalobetasol 0.05% ointment\
3-wk prednisone taper (60 mg: 40:20)\
4-mo isotretinoin taper (40 mg: 20:20:10)Marked clinical improvement without recurrence at 24 mo354FemaleHispanicSjogren syndrome, fibromyalgiaHalobetasol 0.05% ointment\
3-wk prednisone taper (60 mg: 40:20)\
3-mo isotretinoin taper (20 mg: 20:10)Marked clinical improvement but with subjective recurrence at 2 mo454FemaleHispanicDM II, HTNHalobetasol 0.05% ointment\
3-wk prednisone taper (60 mg: 40:20)\
1-mo isotretinoin, 20 mg/dComplete resolution without recurrence at 2 mo[^2]

Limitations of this series include a small sample size limited to only adult female Hispanic patients. Nonetheless, this observation provides insight for a readily available therapy that may improve pigmentation and arrest disease activity in a historically recalcitrant disorder. Larger, long-term observational or prospective studies are warranted to determine the optimal length of treatment to produce clinical resolution and prevent relapse.
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[^1]: *NA*, Not available; *UVB*, ultraviolet B.

[^2]: *DM*, Diabetes mellitus; *HTN*, hypertension.
